Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 6/20 | 0.37 |
| ▸ | MDM4 | O15151 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 3/20 | 0.35 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.35 |
| ▸ | GUCY1B2 | O75343 | 1/20 | 0.35 |
| ▸ | GUCY1A2 | P33402 | 1/20 | 0.35 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.35 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.35 |
| ▸ | SCN1A | P35498 | 1/20 | 0.34 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL982027 | 0.91 | BRD4 (0.37) | KDM5AHTR7PAK1KMT2A | |
| SCHEMBL984600 | 0.91 | BTK (0.40) | KDM5AMDM4HTR7PAK1BTK | |
| SCHEMBL983643 | 0.90 | MDM4 (0.36) | KDM5AMDM4PAK1GUCY1B2GUCY1A2 | |
| SCHEMBL983742 | 0.89 | MCHR1 (0.35) | KDM5APAK1 | |
| SCHEMBL985429 | 0.89 | PAK1 (0.38) | KDM5AMDM4PAK1KMT2A | |
| SCHEMBL982592 | 0.89 | PAK1 (0.38) | KDM5AMDM4PAK1KMT2A | |
| SCHEMBL982594 | 0.89 | BTK (0.42) | BTKKMT2A | |
| SCHEMBL986013 | 0.88 | MEN1 (0.46) | KMT2A | |
| SCHEMBL984790 | 0.88 | PAK1 (0.38) | MDM4HTR7PAK1BTKKMT2A | |
| SCHEMBL983123 | 0.87 | PARP1 (0.45) | BTKNPSR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2011-01-27 | — | — | US | claimed |
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | PDE5A, PDE3A, PDE2A | KDM5A 263/4885MDM4 2898/4885HTR7 3218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.